Small Cap Feast
Small Cap Feast – 20 May 2020
Dish of the Day:
No Joiners Today
No Joiners Today
Off the Menu:
No Leavers Today
No Leavers Today
What’s Cooking in the IPO Kitchen?
The pantry is empty, again!
Renalytix AI 430p £256m (RENX.L)
The commercial-stage artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and lower healthcare costs, announces that its wholly-owned subsidiary, Renalytix AI, Inc. has entered into a joint venture with the Icahn School of Medicine at Mount Sinai, Kantaro Biosciences, LLC , to develop and scale production of COVID-19 antibody test kits.
- Mount Sinai and Renalytix AI, Inc. form joint venture, Kantaro, to develop and scale production of covid antibody test kits
- Kantaro has partnered with Bio-Techne Corporation (NASDAQ: TECH) for manufacturing and global kit distribution
- Scaled kit production planned to enable clinical laboratories to conduct 10M tests per month beginning July
World High Life 8p £11.7m (AQUIS:LIFE)
wholly owned subsidiary, Love Hemp Ltd, has increased capacity for its LH Botanicals business with new machinery and technology to meet growing demand.
Established by the founders of Love Hemp, Tony Calamita and Thomas Rowland, the London-headquartered company, LH Botanicals provides a complete range of CBD products for wholesale, bulk and white label, with all products certified THC-free in customisable bottle sizes, concentrations, and flavours.
The Company has found that demand for LH Botanicals’ CBD products is continuing to rise and, as noted within the Company’s announcement on 7 May 2020, the Company has responded by increasing production capacity by acquiring a new capsule machine and a new bath bomb machine to extend its product offerings in an attempt to increase market share further.
Bango 146.5p £109m (BGO.L)
The mobile commerce company, has successfully launched carrier billing routes in the Google Play store for new operators in Asia, Latin America and Africa. Millions of customers in Peru, Hong Kong and South Africa can now pay for the massive array of content and services in Google Play, charging the cost to their phone bill, all powered by the Bango Platform.
In the space of six weeks, Direct Carrier Billing in the Google Play store has been enabled through the Bango Platform for subscribers of Entel in Peru, Sun Mobile in Hong Kong and MTN in South Africa. Pre and post-paid subscribers can now simply click-to-buy using carrier billing for instant access to their favorite games, music, movies and more.
Creo Medical 141p £222m (CREO.L)
The medical device company focused on the emerging field of surgical endoscopy, announces that it has signed a commercialisation agreement with the Department of Health and Social Care to provide NHS Hospitals with access to the Company’s CROMA Advanced Energy Platform and associated devices for use in Gastrointestinal therapeutic endoscopy at preferential rates for a limited period.
The National Institute for Health Research Invention for Innovation Programme supported certain development projects that Creo undertook via a series of funding awards between 2010 and 2015, totalling close to £2 million. In accordance with the terms of such funding, Creo has entered into this commercialisation agreement, which is designed to aid the roll-out of CROMA and accompanying consumable GI devices in the UK. The agreement also provides for training for clinicians and nurses on the use of Creo’s suite of advanced energy surgery products.
Avacta 140p £291m (AVCT.L)
Avacta has entered into an exclusive distribution agreement with Medusa19 Limited for direct-to-consumer sales of a saliva-based rapid test for the COVID-19 antigen.
Avacta recently announced a partnership with Cytiva (formerly GE Healthcare Life Sciences) to develop a saliva-based rapid antigen test to indicate whether a person has the COVID-19 infection which will be in the form of a simple test strip. The test is intended to give a result within minutes and for use by both healthcare professionals and consumers.
The Group has agreed an exclusive distribution agreement with Medusa19 for the supply of the COVID-19 rapid test direct to consumers globally, subject to the necessary regulatory approvals. Medusa19 has been established by Richard Hughes and Mahmud Kamani, both founder shareholders of Boohoo.com and shareholders of Avacta1, to build a global consumer self-testing business. Medusa19’s initial focus will be on COVID-19 home testing and it is currently investing in global e-commerce, logistics and customer support infrastructure in preparation for Avacta’s COVID-19 test launch. Medusa19 will also have non-exclusive rights to supply the tests to businesses for workforce testing. The distribution agreement includes a profit-sharing arrangement.
VR Education 9.5p £18.35m (VRE.L)
The virtual reality technology company focused on the education and enterprise training space, announces that HTC Corporation has agreed to invest EUR3.0 million (at 5.47p) in the Company and that HTC and the Company are entering into a strategic partnership for the distribution and license of the Company’s ENGAGE platform globally through HTC enterprise sales channels.
HTC’s investment follows the success of the 2020 HTC VIVE Ecosystem Conference which was hosted on the Company’s ENGAGE platform in March 2020.
Mosman Oil & Gas 0.165p £1.9m (MSMN.L)
Mosman has today entered into a Contract for the sale of Welch with the US based Eagle Natural Resources LLC for US$300,000 (cA$460,000).
A deposit of US$30,000 has been received, and the sale will be effective on receipt of the balance of the funds which is expected to take place within 30 days.
Whilst the Welch oil field is producing and has development potential, the ranking of projects in the Strategic Review identified better growth assets at Stanley and Greater Stanley. The capital from the sale of Welch will facilitate investment in these growth areas, as well as providing working capital at a time when cash flow is adversely affected by the low oil price.
The gross profit from operations at Welch project for the six months ending 31 December 2019 was A$264,619. In the 30 June 2019 Financial year Welch recorded a Gross Profit of A$166,229, and the carrying value of Welch at 31 December 2019 was A$500,000.
Tern 10.9p £30.9m (TERN.L)
Tern has used the approximately £1.1 million of cash flow loan monies outstanding from its portfolio company, Wyld Networks Limited as at 19 May 2020 to apply for the subscription of a secured convertible loan note (“CLN”) in Wyld of the same amount.
Tern is also pleased to announce that Wyld has also signed an agreement with Highland Health Ventures Ltd (“HHVL”) to test and deploy its technology into certain care homes in Scotland with the aim of helping to protect and prevent the spread of COVID-19 and other viruses. HHVL is an independent company with a collaboration agreement with NHS Highland for the purpose of developing innovations in healthcare.
Wyld’s technology is to be used to provide digital access and anonymised social distance monitoring and alerting through a mobile application and a mesh wireless network of connected smartphones and IoT devices.
Malvern International 0.225p £0.6m (MLVN.L)
The global learning and skills development partner, today announces that the Company is carrying out an equity fundraising to raise gross proceeds of approximately £1.17 million by way of a placing to raise up to £0.79 million and a subscription to raise approximately £0.38 million in each case at a price of 0.15 pence per share. The Issue Price represents a discount of approximately 61 per cent. to the closing mid-market price of 0.38 pence per Existing Ordinary Share on 19 May 2020.
AorTech 90p £14.6m (AOR.L)
The holding company of a group of medical device businesses focused on the exploitation of the world’s leading long-term implantable biostable polymer , announced that its subsidiary, RUA Medical Devices Limited, has successfully applied for, and been awarded, the maximum grant under a Scottish Government Covid-19 support scheme, The Pivotal Enterprise Resilience Fund (PERF)
RUA Medical has received a total of £150,000 of Government grant support through the Pivotal Enterprise Resilience Fund administered by Scottish Enterprise. This grant will be used to support the working capital and ongoing business needs of RUA Medical.
0203 764 2344
*A corporate client of Hybridan LLP
This document, which does not constitute research, has been issued by Hybridan LLP for information purposes only and should not be construed in any circumstances as an offer to sell or solicitation of any offer to buy any security or other financial instrument, nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to any such action. This document has no regard for the specific investment objectives, financial situation or needs of any specific person or entity and is not a personal recommendation to any such person or entity. Recipients should reach an individual investment decision, based upon their respective financial objectives and financial resources and, if any doubt, should seek advice from an investment advisor.
The information contained in this document is based on materials and sources that are believed to be reliable; however, such information has not been independently verified and therefore it is not possible to confirm such information as being accurate. This document is not intended to be a complete statement or summary of any securities, markets, reports or developments referred to herein. No representation or warranty, either express or implied, is made or accepted by Hybridan LLP, its members, officers, employees, agents or associated undertakings in relation to the accuracy, completeness or reliability of the information contained in this document, nor should it be relied upon as such.
The content of this document includes market commentary and other information which we have prepared in relation to the company referred to in this document, which is our broking client. The provision of this document to you constitutes a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of Regulation 600/2014/EU (MIFID II Regulation).
Any and all opinions expressed are current as of the date appearing on this face of this document only. Any and all opinions expressed are subject to change without notice and Hybridan LLP is under no obligation to update the information contained herein. To the fullest extent permitted by law, none of Hybridan LLP, its members, officers, employees, agents or associated undertakings shall have any liability whatsoever for any direct or indirect or consequential loss or damage (including lost profits) arising in any way from use of all or any part of the information in this document.
This document should not be relied upon as being an independent or impartial view of the subject matter and, for the avoidance of doubt, constitutes non-independent research (as such term is defined in the Financial Conduct Authority’s Conduct of Business Sourcebook to reflect the requirements of the MIFID II Regulation and Directive 2014/65/EU (known as MIFID II)). The individuals who prepared this document may be interested in shares in the company concerned and/or other companies within its sector, may be involved in providing other financial services to the company or companies referenced in this document or to other companies who might be said to be competitors of the company or companies referenced in this document. As a result both Hybridan LLP and the individual members, officers and/or employees who prepared this document may have responsibilities that conflict with the interests of the persons who receive this document. Hybridan LLP and/or connected persons may, from time to time, have positions in, make a market in and/or effect transactions in any investment or related investment mentioned herein and may provide financial services to the issuers of such investments.
In the United Kingdom, this document is directed at and is for distribution only to persons who (i) fall within article 19(5) (persons who have professional experience in matters relating to investments) or article 49(2) (a) to (d) (high net worth companies, unincorporated associations, etc.) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (SI 2005/1529) (as amended) or (ii) persons who are each a professional client or eligible counterparty (as those terms are defined in the Financial Conduct Authority’s Conduct of Business Sourcebook) of Hybridan LLP (all such persons referred to in (i) and (ii) together being referred to as relevant persons). This document must not be acted on or relied up on by persons who are not relevant persons. For the purposes of clarity, this document is not intended for and should not be relied upon by any person who would be classified as a retail client under the Financial Conduct Authority’s Conduct of Business Sourcebook.
Neither this document, nor any copy of part thereof may be distributed in any other jurisdictions where its distribution may be restricted by law and persons into whose possession this document comes should inform themselves about, and observe, any such restrictions. Distribution of this report in any such other jurisdictions may constitute a violation of territorial and/or extra-territorial securities laws, whether in the United Kingdom, the United States or any other jurisdiction in any part of the world.
Where possible this document is made available to all relevant recipients at the same time. Dissemination of research by Hybridan LLP is monitored to ensure that it is only provided to relevant persons. Research prepared by Hybridan LLP is not intended to be received and/or used by any person who is a retail client.
Hybridan LLP and/or its associated undertakings may from time-to-time provide investment advice or other services to, or solicit such business from, any of the companies referred to in this document. Accordingly, information may be available to Hybridan LLP that is not reflected in this material and Hybridan LLP may have acted upon or used the information prior to or immediately following its publication. In addition, Hybridan LLP, the members, officers and/or employees thereof and/or any connected persons may have an interest in the securities, warrants, futures, options, derivatives or other financial instrument of any of the companies referred to in this document and may from time-to-time add or dispose of such interests.
This document may not be copied, redistributed, resent, forwarded, disclosed or duplicated in any form or by any means, whether in whole or in part other than with the prior written consent of Hybridan LLP.
MIFID II status of Hybridan LLP research
The cost of production of our corporate research is met by retainers from our corporate broking clients. In addition, from time to time we issue further communications as market commentary (such as our daily newsletter, Small Cap Breakfast), which we consider to constitute a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of the MIFID II Regulation.
Hybridan LLP is a limited liability partnership registered in England and Wales, registered number OC325178, and is authorised and regulated by the Financial Conduct Authority and is a member of the London Stock Exchange. Any reference to a partner in relation to Hybridan LLP is to a member of Hybridan LLP or an employee with equivalent standing and qualifications. A list of the members of Hybridan LLP is available for inspection at the registered office, 2 Jardine House, The Harrovian Business Village, Bessborough Road, Harrow, Middlesex HA1 3EX.
If you would like to unsubscribe, please email email@example.com with “unsubscribe me”.